arrow_back Back Filing freshness 10-Q Q1 FY2027 SEC EDGAR

HAEMONETICS CORP

HAE
$106.92 ▼ -1.66 (-1.53%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
71 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
64
Health
Fair
Bearish
auto_awesome

Analytical Summary

HAEMONETICS CORP faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $4.8B
Dividend Yield
Revenue Growth 5.6%
Op. Margin 16.9%
ROIC 2.0%
FCF / Share $0.98
Trailing P/E 146.5x
Price / Book 5.8x
FCF Yield 0.9%
Debt / Equity 1.42
info Valuation on last close. End-of-day price, Sep 23, 2026.

71-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$339.38M
↑ +5.6%
Net Income Profit after all expenses
$33.01M
↓ -3.0%
Operating Margin Operating profit as % of sales
16.9%
↑ +354.7% 70th
FCF / Share Free cash flow per share
$0.98
↑ +245.4%
Long-Term Debt Long-term obligations
$1.19B
↓ -4.2%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability
69
Returns
65
Financial Health
45
Cash Quality
89

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 19 years · 71 quarters